{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:08:17Z","timestamp":1783451297066,"version":"3.55.0"},"reference-count":65,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>No head-to-head trials have compared the efficacy and safety between the licensed dosage and administration dosage of dupilumab and benralizumab for inadequately controlled asthma. We conducted an indirect treatment comparison to estimate differences in the efficacy and safety between dupilumab and benralizumab for inadequately controlled asthma using the Bayesian approach. The primary efficacy endpoint was annual exacerbation rate (AER). A subgroup analysis by blood eosinophil count was also performed. The primary safety endpoint was the incidence of any adverse events (AAEs). The results demonstrate that there was no significant difference in the AER between dupilumab and benralizumab in overall patients and the subgroup with the blood eosinophil count of &lt;150. However, the AER was significantly lower in the dupilumab group than in the benralizumab group in the subgroup with a blood eosinophil count of \u2265150 but &lt;300, and \u2265300 with the rate ratio and 95% credible interval of 0.51 (0.29\u20130.92) and 0.58 (0.39\u20130.84), respectively. There was no significant difference in the AAEs between the dupilumab and benralizumab groups. This indirect treatment comparison indicates that dupilumab is superior to benralizumab in patients with inadequately controlled asthma having higher blood eosinophil counts. A direct comparison is required to provide definitive evidence. Systematic Review Registration: UMIN-CTR no. UMIN000036256.<\/jats:p>","DOI":"10.3390\/ijms21030889","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T01:25:51Z","timestamp":1580693151000},"page":"889","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-8279","authenticated-orcid":false,"given":"Koichi","family":"Ando","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sagara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"To, T., Stanojevic, S., Moores, G., Gershon, A.S., Bateman, E.D., Cruz, A.A., and Boulet, L. (2012). Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health, 12.","DOI":"10.1186\/1471-2458-12-204"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ACI.0000000000000346","article-title":"Asthma guidelines: The Global Initiative for Asthma in relation to national guidelines","volume":"17","author":"Becker","year":"2017","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/02770900903518835","article-title":"Factors associated with the control of severe asthma","volume":"47","author":"Hermosa","year":"2010","journal-title":"J. Asthma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.rmed.2006.03.031","article-title":"Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment","volume":"100","author":"Peters","year":"2006","journal-title":"Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1067\/mai.2001.116435","article-title":"Cytokine-directed therapies for asthma","volume":"108","author":"Barnes","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cpt.11","article-title":"Anti-interleukin therapy in asthma","volume":"97","author":"Dunn","year":"2015","journal-title":"Clin Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.amjmed.2014.05.006","article-title":"Getting control of uncontrolled asthma","volume":"127","author":"Wechsler","year":"2014","journal-title":"Am. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"g5517","DOI":"10.1136\/bmj.g5517","article-title":"Asthma: Pathogenesis and novel drugs for treatment","volume":"349","author":"Olin","year":"2014","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cpt.284","article-title":"Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma","volume":"99","author":"Mitchell","year":"2016","journal-title":"Clin Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2015.00353","article-title":"Regulation of T cell immunity in atopic dermatitis by microbes: The Yin and Yang of cutaneous inflammation","volume":"6","author":"Biedermann","year":"2015","journal-title":"Front Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jdermsci.2007.06.001","article-title":"Complex regulation of S100A8 by IL-17, dexamethasone, IL-4 and IL-13 in HaCat cells (human keratinocyte cell line)","volume":"47","author":"Bai","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014Part II: Immune cell subsets and therapeutic concepts","volume":"127","author":"Nograles","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J. Allergy Clin Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14712598.2013.758708","article-title":"New era of biologic therapeutics in atopic dermatitis","volume":"13","author":"Dhingra","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"125","article-title":"The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: A review","volume":"8","author":"Patterson","year":"2015","journal-title":"J. Asthma Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: Subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14712598.2017.1387245","article-title":"Dupilumab for the treatment of asthma","volume":"17","author":"Pelaia","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2017.1316194","article-title":"Benralizumab for the treatment of asthma","volume":"13","author":"Saco","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin Epidemiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1067\/mai.2001.119149","article-title":"The trials and tribulations of IL-5, eosinophils, and allergic asthma","volume":"108","author":"Inman","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2003.08.015","article-title":"Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF","volume":"112","author":"Huston","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2012.07.027","article-title":"Novel targeted therapies for eosinophilic disorders","volume":"130","author":"Wechsler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jaci.2013.08.006","article-title":"A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease","volume":"133","author":"Romeo","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7326\/0003-4819-152-4-201002160-00008","article-title":"Narrative review: The role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes","volume":"152","author":"Levine","year":"2010","journal-title":"Ann Intern Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1378\/chest.130.1.244","article-title":"Cytokines or their antagonists for the treatment of asthma","volume":"130","year":"2006","journal-title":"Chest"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568010023344661","article-title":"IL-4 and IL-13: Their pathological roles in allergic diseases and their potential in developing new therapies","volume":"1","author":"Izuhara","year":"2002","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","article-title":"Strategies targeting the IL-4\/IL-13 axes in disease","volume":"75","author":"May","year":"2015","journal-title":"Cytokine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4889(02)00318-X","article-title":"Structure, binding, and antagonists in the IL-4\/IL-13 receptor system","volume":"1592","author":"Mueller","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1183\/09059180.00007609","article-title":"Investigational therapeutics targeting the IL-4\/IL-13\/STAT-6 pathway for the treatment of asthma","volume":"19","author":"Oh","year":"2010","journal-title":"Eur. Respir. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/187221310793564281","article-title":"Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease","volume":"4","author":"Steinke","year":"2010","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/1744666X.2016.1216316","article-title":"Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma\u2014An update","volume":"13","author":"Walsh","year":"2017","journal-title":"Expert Rev. Clin Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF03256608","article-title":"Biology and therapeutic potential of the interleukin-4\/interleukin-13 signaling pathway in asthma","volume":"1","author":"Corry","year":"2002","journal-title":"Am. J. Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 inflammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_47","unstructured":"Higgins, J.P.T., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration: Wiley-Blackwell. Version 5.1. 0."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: Heterogeneity--subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Making"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e5182","DOI":"10.1136\/bmj.e5182","article-title":"The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review","volume":"345","author":"Ford","year":"2012","journal-title":"BMJ"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","article-title":"Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: A systematic review and indirect comparison of clinical effectiveness","volume":"101","author":"Liu","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12325-016-0299-4","article-title":"Efficacy and Safety of Aclidinium\/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison","volume":"33","author":"Medic","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1185\/03007995.2012.734798","article-title":"Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: An indirect comparison using Bayesian network meta-analysis","volume":"28","author":"Cure","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1185\/03007995.2016.1140026","article-title":"An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis","volume":"32","author":"Betts","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e009122","DOI":"10.1136\/bmjopen-2015-009122","article-title":"Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: An indirect treatment comparison","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","article-title":"Systematic review with network meta-analysis: Indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease","volume":"54","author":"Miwa","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_62","unstructured":"Dias, S., Welton, N.J., Sutton, A.J., and Ades, A.E. (2011). NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials, National Institute for Health and Clinical Excellence (NICE)."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/009286159102500307","article-title":"Using prior findings to augment active-controlled trials and trials with small placebo groups","volume":"25","author":"Gould","year":"1991","journal-title":"Drug Inf. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph Stat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1008820505350","article-title":"Convergence assessment techniques for Markov chain Monte Carlo","volume":"8","author":"Brooks","year":"1998","journal-title":"Stat. Comput."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/889\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:11Z","timestamp":1760172791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21030889"],"URL":"https:\/\/doi.org\/10.3390\/ijms21030889","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}